What’s even more inspiring is growing novel targeted agents such as BTK inhibitor Ibrutinib [9,10], BCL2 inhibitor Venetoclax [11,12], PI3K inhibitor CUDC-907 [13], and AKT inhibitor MK-2206 [14], etc. have shown promising therapeutic potential in relapsed/refractory DLBCL. The gene discussed is AKT1; the disease is diffuse large B-cell lymphoma.